We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $2.33, demonstrating a -3.72% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.01% for the day. On the other hand, the Dow registered a loss of 0.32%, and the technology-centric Nasdaq increased by 0.05%.
Prior to today's trading, shares of the company had gained 2.54% outpaced the Medical sector's loss of 1.59% and lagged the S&P 500's gain of 5.37%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be -$0.15, reflecting a 44.44% increase from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.17 per share and a revenue of $8.77 million, representing changes of +83.81% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 82, placing it within the top 34% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $2.33, demonstrating a -3.72% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.01% for the day. On the other hand, the Dow registered a loss of 0.32%, and the technology-centric Nasdaq increased by 0.05%.
Prior to today's trading, shares of the company had gained 2.54% outpaced the Medical sector's loss of 1.59% and lagged the S&P 500's gain of 5.37%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be -$0.15, reflecting a 44.44% increase from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.17 per share and a revenue of $8.77 million, representing changes of +83.81% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 82, placing it within the top 34% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.